Kura Oncology, Inc.
NASDAQ:KURA
8.98 (USD) • At close December 26, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Kura Oncology, Inc. |
Symbool | KURA |
Munteenheid | USD |
Prijs | 8.98 |
Beurswaarde | 698,318,026 |
Dividendpercentage | 0% |
52-weken bereik | 8.75 - 24.17 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Troy Edward Wilson J.D., Ph.D. |
Website | https://kuraoncology.com |
An error occurred while fetching data.
Over Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)